

## DERMATOLOGY

### USA

- Strategic acquisition of North American Dermatology focused CRO: HillTop Research
- Opportunity to execute studies in multiple locations with multiple climatic conditions in N. America and/or India
- Capability for conducting trials : Both in-house environment or on an outpatient basis.
- Cliantha also specializes in Occlusive Dermal Delivery System also known as "Hill Top Chambers"

PHASE	INDICATION	# OF SUBJECTS
Phase III	Acne	825
		705
		1050
		965
		825
		825
		100
		753
		1000
		1000
	Psoriasis	100
	Rosacea	1008
		1100
	Tinea Pedis	931
		690

### INDIA (LATE PHASE)

- We have access to over 400 Dermatologists who have the experience of conducting clinical trials.
- Having an Operation team in USA gives us the capabilities to do studies in India, USA and Latin America also.

20  
Studies

08  
Indications

>350  
Sites

>10k  
Patients

#### Expertise in:

- Transdermal/Topical Bioequivalence
- Contact Sensitization- Human Repeat Insult Patch Test (HRIPT)
- Vasoconstriction studies
- Adhesion studies
- PK studies
- Cosmetics, Skin , Hair care studies
- Efficacy End-point studies

INDICATION	MOLECULE	REGULATORY	SITES	# OF PATIENTS
Acne Vulgaris	Clindamycin & Benzoyl Peroxide	DCGI	10	60
		USFDA	26	850
		EU	20	530
		USFDA	20	910
	Adapalene BPO	USFDA	20	650
		EU	20	550
	Tretinoin 0.025 %	USFDA	20	1060
		USFDA	20	715
Tretinoin 0.1 %	USFDA	18	570	
	USFDA	20	612	
Atopic Dermatitis	Roflumilast 0.30%	USFDA	20	525
Ichthyosis Vulgaris	Ammonium Lactate 12 %	USFDA	20	390
		USFDA	20	390
Psoriasis	Dimethyl Fumarate	EU	20	300
Scabies	Permethrine	USFDA	10	154
		USFDA	10	154
		DCGI	2	18
Secondary infected traumatic skin lesions	Mupirocin	USFDA	25	990
Tinea pedis	Ketoconazole 2%	USFDA	25	794
Tinea versicolor		USFDA	14	425